Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma
Status:
Recruiting
Trial end date:
2023-04-23
Target enrollment:
Participant gender:
Summary
This is an open label, single arm, phase I/II for patients with r/r Non-Hodgkin's Lymphoma
. The purpose is to evaluate the safety and efficacy of the combination with Azacytidine,
Bendamustine and Piamprizumab